{"groups":[{"description":"Participants will receive 27 mg/m\\^2 of Carfilzomib on Days 1, 2, 8, 9, 15, \\& 16 and 70 mg/m\\^2 of Bendamustine by IV on days 1 \\& 2 in a 28-day cycle. Study treatment will be given until 8 cycles of treatment are completed or until disease progression, whichever comes first. 20 mg Dexamethasone will be administered by PO or IV on Days 1, 2, 8, 9, 15, 16, 22, \\& 23 of each 28-day cycle.","id":"FG000","title":"Carfilzomib 27 mg/m^2, Bendamustine 70 mg/m^2, Dexamethasone 20 mg"},{"description":"Participants will receive 36 mg/m\\^2 of Carfilzomib on Days 1, 2, 8, 9, 15, \\& 16 and 70 mg/m\\^2 of Bendamustine by IV on days 1 \\& 2 in a 28-day cycle. Study treatment will be given until 8 cycles of treatment are completed or until disease progression, whichever comes first. 20 mg Dexamethasone will be administered by PO or IV on Days 1, 2, 8, 9, 15, 16, 22, \\& 23 of each 28-day cycle.","id":"FG001","title":"Carfilzomib 36 mg/m^2, Bendamustine 70 mg/m^2, Dexamethasone 20 mg"},{"description":"Participants will receive 36 mg/m\\^2 of Carfilzomib on Days 1, 2, 8, 9, 15, \\& 16 and 90 mg/m\\^2 of Bendamustine by IV on days 1 \\& 2 in a 28-day cycle. Study treatment will be given until 8 cycles of treatment are completed or until disease progression, whichever comes first. 20 mg Dexamethasone will be administered by PO or IV on Days 1, 2, 8, 9, 15, 16, 22, \\& 23 of each 28-day cycle.","id":"FG002","title":"Carfilzomib 36 mg/m^2, Bendamustine 90 mg/m^2, Dexamethasone 20 mg"},{"description":"Participants will receive 45 mg/m\\^2 of Carfilzomib on Days 1, 2, 8, 9, 15, \\& 16 and 90 mg/m\\^2 of Bendamustine by IV on days 1 \\& 2 in a 28-day cycle. Study treatment will be given until 8 cycles of treatment are completed or until disease progression, whichever comes first. 20 mg Dexamethasone will be administered by PO or IV on Days 1, 2, 8, 9, 15, 16, 22, \\& 23 of each 28-day cycle.","id":"FG003","title":"Carfilzomib 45 mg/m^2, Bendamustine 90 mg/m^2, Dexamethasone 20 mg"},{"description":"Participants will receive 56 mg/m\\^2 of Carfilzomib on Days 1, 2, 8, 9, 15, \\& 16 and 90 mg/m\\^2 of Bendamustine by IV on days 1 \\& 2 in a 28-day cycle. Study treatment will be given until 8 cycles of treatment are completed or until disease progression, whichever comes first. 20 mg Dexamethasone will be administered by PO or IV on Days 1, 2, 8, 9, 15, 16, 22, \\& 23 of each 28-day cycle.","id":"FG004","title":"Carfilzomib 56 mg/m^2, Bendamustine 90 mg/m^2, Dexamethasone 20 mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Dose Level 1"},{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Dose Level 2"},{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Dose Level 3"},{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Dose Level 4"},{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"15"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"15"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Dose Level 5"}],"preAssignmentDetails":"23 participants signed a consent form; 2 were screen fails and 1 was removed from the study prior to the study start and did not receive the study interventions."}